Why McKesson Stock Jumped 40%?
Between August 29, 2025, and February 25, 2026, McKesson (MCK) surged 41%, driven by a powerful mix of oncology segment growth and core business acceleration. As margins expanded and strategic shifts sharpened focus on high-growth markets, investors rewarded the company’s renewed momentum and rising profitability.
Below is an analytical breakdown of stock movement into key contributing metrics.
| 8292025 | 2252026 | Change | |
|---|---|---|---|
| Stock Price ($) | 685.2 | 963.2 | 40.6% |
| Total Revenues ($ Mil) | 377,595.0 | 397,958.0 | 5.4% |
| Net Income Margin (%) | 0.8% | 1.1% | 30.1% |
| P/E Multiple | 27.0 | 27.3 | 1.1% |
| Shares Outstanding (Mil) | 124.9 | 123.2 | 1.4% |
| Cumulative Contribution | 40.6% |
So what is happening here? A strong 41% stock surge was fueled by a 5.4% revenue rise, a 30% boost in net income margin, and steady P/E multiples, highlighting improved profitability and investor confidence.
Here Is Why McKesson Stock Moved
- Freeport-McMoRan Earnings: The Good, the Bad, and the Grasberg
- Can Newmont Keep Riding The Gold Rally Into 2027?
- Intel, Lam, KLA: Will Musk’s $120B Terafab Boost These Stocks?
- Get Paid 10% To Buy NVDA At A 30% Discount, Here’s How
- How CVS Health’s Transformation Is Facing A Hard Valuation Floor
- Is UBER Stock Undervalued At $80?
- Oncology Segment Growth: Oncology & Multispecialty segment revenues grew 37%, indicating successful platform acquisitions and deepening provider relationships driving higher-margin business mix.
- Core Business Acceleration: Consolidated revenues rose 11% to $106.2 billion, fueled by increased prescription volumes from retail national account customers, showing strong core execution.
- Enhanced Profitability: Adjusted Earnings per Diluted Share increased 16% to $9.34, reflecting strong operational performance and a favorable business mix, leading to raised FY26 guidance.
- Strategic Simplification: Completed the sale of Norwegian businesses, finalizing the exit from Europe to concentrate capital and management focus on higher-growth North American markets.
- Capital Efficiency: Generated $1.1 billion in Free Cash Flow, demonstrating strong cash conversion from operations which enables continued strategic investments and shareholder returns.
Current Assesment Of MCK Stock
The core investment debate is centered around: Can accelerating growth in high-margin Oncology and Biopharma services outrun the recent sharp decline in operating cash flow and looming margin pressure from the Inflation Reduction Act?
The prevailing sentiment appears to be neutral. Elite management and a powerful growth engine in specialty/oncology are fully offset by a wall of worry. The sharp drop in operating cash flow and significant regulatory risks (IRA) counterbalance the positive mix-shift story.
| Bull View | Bear View |
|---|---|
| The strategic pivot to higher-margin segments and GLP-1 distribution is a durable growth engine. The planned separation of the low-growth Medical-Surgical unit will unlock further value. | The significant Q3 drop in operating cash flow is a red flag. Future margins are structurally threatened by IRA price negotiations, creating a potential guidance risk for FY27. |
Navigating the competing bull and bear cases of any single stock carries inherent volatility. Managing that idiosyncratic risk requires a broader portfolio framework.
Portfolios Win When Stock Picks Fall Short
Individual stocks can soar or tank but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside and mitigate the downside associated with any individual stock.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.